Scandinavian ChemoTech signs agreement with new distributor in India

A distribution agreement, that ChemoTech negotiated during the Sweden state visit to India, was signed today with a new distributor for Delhi and north of India.

ChemoTech has secured a distribution agreement with Horizon Medical Technologies for Northern India in the states of Jammu, Kashmir, Punjab, Haryana, Rajasthan, Uttar Pradesh, Uttarakhand, Himachal Pradesh and the Union Territories Delhi, Chandigarh, Leh & Ladakh.


Horizon Medical Technologies is a distributor with more than 15 years of experience in distribution and business development in the field of medical devices. They have successfully worked with Dräger, Smith Medical, Zimmer Bio Met, among others and has more than 20 private hospitals and hospital groups in northern India as their customers and to which they will now start marketing IQwave™ and Tumour Specific Electroporation™.


“This is a very important contract for us as we have searched for a long time for a distributor that has a special edge in business development within this region. We are very excited to start to market the IQwave™ in this important part of India. As in any other country it is of great importance to be present in the capital and especially in India where most of the federal decisions are being made.” - Mohan Frick Co-founder and CEO of Scandinavian ChemoTech.
 

IN SWEDISH: 

Scandinavian ChemoTech tecknar avtal med ny distributör i Indien


En förhandling, som ChemoTech påbörjade under det svenska statsbesöket, har idag resulterat i ett nytt distributionsavtal för Delhi och norra Indien.


ChemoTech har tecknat ett distributionsavtal med Horizon Medical Technologies för norra Indien och staterna Jammu, Kashmir, Punjab, Haryana, Rajasthan, Uttar Pradesh, Uttarakh and, Himachal Pradesh Delhi, Chandigarh, Leh och Ladakh.


Horizon Medical Technologies är en distributör med mer än 15 års erfarenhet av distribution och affärsutveckling inom området medicintekniska produkter. De har med framgång arbetat med bland annat Dräger, Smith Medical, Zimmer Bio Met. och har mer än 20 privata sjukhus och sjukhusgrupper i norra Indien som kunder och till vilka de nu kommer att börja marknadsföra IQwave ™ och Tumour Specific Electroporation ™.


”Detta är ett viktigt kontrakt för oss och vi är glada att vi funnit en distributör som har en speciell inriktning mot affärsutveckling i denna region. Vi ser fram emot att börja marknadsföra IQwave ™ i denna viktiga del av Indien. Liksom i alla andra länder är det av stor vikt att vara närvarande i huvudstaden och särskilt i Indien där de flesta federala beslut fattas. ”- Mohan Frick, VD för Scandinavian ChemoTech.

 

 

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

info@chemotech.se

 

 

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe